Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBXR23)

Drug Name

BMN-110 Drug Info

Synonyms

Enzyme replacement therapy (iv infusion, MPS IVA), BioMarin; Enzyme replacement therapy (iv infusion, Morquio A syndrome), BioMarin; Enzyme replacement therapy (iv infusion, mucopolysaccharidosis IVA), BioMarin; N-acetylgalactosamine-6-sulfatase (GALNS) (Morquio A syndrome), BioMarin

Indication

Disease Entry	ICD 11	Status	REF
Morquio syndrome	5C56.32	Phase 3	[1]

Cross-matching ID

TTD Drug ID: DMBXR23

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting N-acetylgalactosamine 6 sulfatase (GALNS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Elosulfase alfa	DMA9REV	Mucopolysaccharidosis	5C56.3	Approved	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-acetylgalactosamine 6 sulfatase (GALNS)	TTT9YPO	GALNS_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01415427) Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome). U.S. National Institutes of Health.
2	Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014 Nov;37(6):979-90.
3	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.